SCHEMBL16100768

SCHEMBL16100768

O=C1CCCN(C(=O)O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.34
INMT O95050 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
THRB P10828 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
TSHR P16473 2/20 0.32
NOTUM Q6P988 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704455 0.88 LMNA (0.37) LMNAHTT
SCHEMBL25251712 0.80 LMNA (0.39) LMNASMN1; SMN2INMTALDH1A1KMT2A
SCHEMBL31098685 0.79 LMNA (0.42) LMNATSHR
SCHEMBL59155 0.78
SCHEMBL839318 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A
SCHEMBL1857819 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A
Ammonia Solution, Strong SCHEMBL4654664 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A
SCHEMBL2297517 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A
SCHEMBL10871994 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A
SCHEMBL3620504 0.76 LMNA (0.59) LMNASMN1; SMN2INMTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 WO disclosed
EP-3820532-A2 DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) 2021-05-19 EP disclosed
CN-109790143-A Amine-linked C for target protein degradation3-glutarimide solution stator body C4医药公司 2019-05-21 CN disclosed
EP-2968339-A1 MK2 INHIBITORS AND USES THEREOF Celgene Avilomics Research, Inc. (US) 2016-01-20 EP disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 WO disclosed
CN-1096054-A Novel process for preparing piperidinedione carboxylate derivatives SMITHKLINE BEECHAM PLC (GB) 1994-12-07 CN disclosed
CN-1096054-A Novel process for preparing piperidinedione carboxylate derivatives SMITHKLINE BEECHAM PLC (GB) 1994-12-07 CN disclosed